Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #343

    But that could be a good quenstion for Jan at the next Q&A

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #344

      i hadn't even though about that- off label sales, good point

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #345

        pls do ask! i have been wondering if this could be the case!

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #346

          If superdara is substantially better than dara it is out of the question, that jnj would NOT opt in. That would the scandal of the century.

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #347

            Horizon earnings call on tepezza
            https://www.fool.com/earnings/call-transcripts/2021/05/05/horizon-therapeutics-plc-hznp-q1-2021-earnings-cal/

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #348

              we spoke of orphan designation on amivantamab; this is how important Horizon thinks it is for tepezza: 'Within Europe we continue to look for avenues to attain orphan drug designation that would be what's required to move to the next step. So until we're able to obtain orphan drug designation we won't be moving forward in Europe.'

              1 Reply Last reply
              0
              • troldmandenT Offline
                troldmandenT Offline
                troldmanden
                wrote on sidst redigeret af
                #349

                Det står direkte i hexa38 kontakten at hvis JnJ IKKE opter ind, så falder rettighederne tilbage til genmab. MEN stoffet må ikke markedsføres i indikationer som dara er godkendt i, virker. Kun dara resistente patienter og indikationer dara ikke er godkendt i. Og så fjernes en meget stor del af værdien. Så det er den klemme JnJ har over genmab

                1 Reply Last reply
                0
                • nohopeN Offline
                  nohopeN Offline
                  nohope
                  wrote on sidst redigeret af
                  #350

                  Det skal være offentligheden der skal redde os. JnJ kan forhåbentligvis ikke holde til at de fremstår som om de vha jura holder Super-Dara væk fra markedet for at beskytte deres indtjening på Dara.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #351

                    @troldmanden i have also read the press release, but i still think my question is valid

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #352

                      Genmab: Oversigt over analyseændringer efter regnskab:
                      https://www.proinvestor.com/investornyt/674829/genmab-oversigt-over-analyseaendringer-efter-regnskab

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        Plimsoller
                        wrote on sidst redigeret af
                        #353

                        Potentielle problemer med Pfilzer og Elranatamab. Artiklen er låst. Winkel affejer tvivl. https://borsen.dk/nyheder/virksomheder/genmab-topchef-affejer-tvivl-om-kraefthaab-efter-problemer-hos-konkurrent

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #354

                          Vi havde det oppe i går og kunne ikke finde noget om perifær neuropati, som vist var problemet med Pfizers bite, hos tecistamab. https://www.businesswire.com/news/home/20201205005041/en/Updated-Results-from-the-Phase-1-Study-of-the-BCMAxCD3-Bispecific-Teclistamab-Show-Preliminary-Efficacy-in-Patients-with-Heavily-Pretreated-Relapsed-or-Refractory-Multiple-Myeloma

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #355

                            teclis..

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #356

                              Lad os se hvad ASCO data siger - begynder at ligne en god mulighed

                              1 Reply Last reply
                              0
                              • troldmandenT Offline
                                troldmandenT Offline
                                troldmanden
                                wrote on sidst redigeret af
                                #357

                                EL det er jo kun mindre PoC studier der bliver lavet i løbet af 2022. Så det er ikke studier der for alvor vil vise kæmpe overlegenhed. Det bliver det ikke poweret til. Så derfor tror jeg ikke det er noget der vil fylde andet end hos genmab investorer og ikke ud i mainstream medier

                                1 Reply Last reply
                                0
                                • troldmandenT Offline
                                  troldmandenT Offline
                                  troldmanden
                                  wrote on sidst redigeret af
                                  #358

                                  Money talks. Hvor barsk og kynisk det end er

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #359

                                    E L - regarding orphan drug designation I believe Horizons patent situation is completely different to Janssens with amivantamab.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #360

                                      Trolmanden det er trods alt det studie Janssen skal beslutte sig ud fra - og tillige kan det give noget vallidering af HexaBody, som trods alt fylder mere og mere.

                                      1 Reply Last reply
                                      0
                                      • troldmandenT Offline
                                        troldmandenT Offline
                                        troldmanden
                                        wrote on sidst redigeret af
                                        #361

                                        Ja i know, sukkerlaf. Min pointe er blot at der er langt fra et PoC studie til at have rock solide data man kan gå ud og vise omverden som verdens nye vidunder stof, men JnJ har begraveet det

                                        1 Reply Last reply
                                        0
                                        • troldmandenT Offline
                                          troldmandenT Offline
                                          troldmanden
                                          wrote on sidst redigeret af
                                          #362

                                          Det er hardcore kynisme og penge der styre. Se bare voldgiften i al almindelighed

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger